The Pleasure Score

The Dose Increase

Eli: The clinicians who treated him later published his case. A 54-year-old man with type 2 diabetes starts semaglutide, the drug in Ozempic, in pill form. Before the first dose, they check his mind, with two standard questionnaires, one for depression and one for anxiety. He scores 3 and 2. Barely a flicker. No psychiatric history, his or his family's. No psychiatric drugs, ever. At week four, his dose goes from 3 milligrams to 7.

Mara: So a before picture, taken on purpose. Something to measure any change against.

Eli: And by week six, there's a change to measure. He describes a state unlike anything he'd felt before. Pervasive low mood. Fatigue. Loss of interest in things that had always mattered to him. Sleeping far longer most nights. Passive thoughts of death, with no plan or intent. On that depression questionnaire, he's now in the moderately severe range.

Mara: Which is what one listener asked us: can Ozempic make a person lose their appetite for life, not just for food? Today's angle is the gap between clinical trial checklists and the neurobiology of pleasure.

Eli: That's the puzzle his doctors were left holding. A drug they'd just stepped up, or a depression that would have arrived anyway, in a man with nothing in his past to predict it.

Mara: Before starting the drug, he couldn't identify a single recent life stressor.

The 'Meh' Effect

Eli: He's not the only one describing something like it. By mid-2026, more than 30 million people in the US were on GLP-1 drugs, medications for blood sugar and appetite. At that scale, even a rare effect touches a lot of lives. Across social media and forums, some describe feeling flat, less excited by things they once enjoyed. There are nicknames for it, the meh effect, Ozempic personality, and none of them is a diagnosis. One Washington Post piece described "a dulled response not just to food but to other sources of joy such as reading, listening to music, dancing, gardening -- or even sex."

Mara: That's the line to hold onto. Losing interest in a second helping is appetite. Losing interest in the gardening is anhedonia, a reduced ability to feel pleasure or reward.

Eli: And doctors quoted in one report say this anhedonia-like effect isn't the same as depression. Several studies even tie GLP-1 therapy to fewer depressive symptoms overall. One woman in that Post reporting had felt off for months. She'd look at a gorgeous birthday cake, or walk outside to a pink-and-purple streaked sunset, and not really enjoy them. It wasn't depression, she said. Everything was just "meh." Our man's doctors drew a similar line. His stomach trouble had been mild and confined to the first week. What dominated was psychological, and those symptoms, they wrote, "are not well explained by a smaller appetite or a few lost kilograms."

Mara: Then there are the health records. A 2024 study examined an obesity-focused cohort. The users had higher rates of major depression, anxiety, and suicidal thoughts or attempts, though what that comparison means is disputed.

Eli: Records side by side show company, not cause. So here's an account with no food in it at all. Dave Knapp, who founded an obesity care podcast called On the Pen, said that after starting GLP-1s, "a lot of the things that used to interest me, just, I could take or leave." His tip-off was Chicago Cubs baseball. He'd followed the team very closely for many, many years. Then he realized it had been a couple of years since he'd really followed it at all.

Mara: Years of a team gone quiet.

Eli: Then he adjusted his medication. After a few weeks, he said, "my head started to clear up. The sun started to shine a little bit brighter." His zest came back, Cubs baseball included. What no account like his explains, Mara, is how a drug for blood sugar and appetite reaches a ballgame.

Crossed Circuits

Mara: It starts with where the receptors sit. These drugs have been shown to cross into the brain, and GLP-1 receptors there turn up in areas for appetite and emotion, like the hypothalamus and the amygdala. They're also in the reward system, including the ventral tegmental area: cells that send dopamine into a region called the nucleus accumbens, the circuit that marks something as worth going after. Joshua Neal describes parts of the dopamine system "that help to determine what feels pleasurable and motivating."

Eli: So Knapp's Cubs and a second helping might run on shared wiring.

Mara: Animal work backs part of that. Preclinical studies suggest semaglutide can blunt the dopamine response to a reward cue, food or drugs, without lowering baseline dopamine. Our man's case-report authors go further. They argue that this dampening in the nucleus accumbens underlies what dominated his picture: lost motivation, lost pleasure.

Eli: Animal models, though. His doctors still had a man to treat.

Mara: So what did they do?

Eli: Kept him on semaglutide and added two antidepressants, vortioxetine and bupropion. It's how doctors pull a side effect apart from a depression: treat the mood, then take the suspect away and watch. By week 12, his depression score was down to 6. Anhedonia gone. Thoughts of death gone. Blood sugar still improving. Then, at week 16, they stopped the semaglutide. Two weeks later, his score held at 5. Here's the snag for any tidy story: his mood had recovered while he was still on the drug.

Mara: And off it, his fasting glucose climbed back to 9.8. His doctors called it a genuine dilemma: one drug, apparently causing harm and providing benefit.

Eli: Whether week six was the drug is still unknown. The animal work points at reward circuits, while regulators combing the big trials found no psychiatric harm. Restarting semaglutide for his blood sugar would put that tension inside one man.

The Blind Spot

Mara: The regulators had looked hard. The FDA pooled 91 placebo-controlled GLP-1 trials. Its finding: no increased risk of suicidal thoughts or behavior versus placebo, and none for anxiety, depression, irritability or psychosis. That held across more than a hundred thousand patients. So in 2026 the FDA asked manufacturers to take the suicidal-thoughts language off certain GLP-1 medication labels. Britain's regulator, the MHRA, also found no causal link.

Eli: A net that size should catch anything real.

Mara: It catches what it's built to catch. In one pooled look at the STEP trials of semaglutide for weight loss, about 3 percent on the drug had depressive symptoms needing a clinical look. On placebo, about the same. Thomas Wadden, one of the researchers, said the analyses give assurance that the medication, "when taken by individuals who are free of significant mental health concerns, does not increase the risk of depression, suicidal thoughts, or suicidal behavior."

Eli: That's who those trials measured?

Mara: And there's the blind spot. If obesity trials leave out people with serious psychiatric histories, and track mood with general depression questionnaires, the kind our man filled in, then blunted pleasure that never tips into clinical depression has nowhere to show up. That STEP analysis didn't report anhedonia separately. And as of August 2026, by one psychiatry practice's account, no large prospective trial in adults on GLP-1s for weight had measured anhedonia directly, with a dedicated tool like the Snaith-Hamilton Pleasure Scale.

Eli: Built to find depression, then, not missing pleasure. Meanwhile his blood sugar needed the drug, so after a short break his doctors restarted semaglutide and climbed the doses again. Before the dose had even stepped up, his depression score was back up to 12. Then it stepped up, at the same step in the climb as the first time, and the score kept rising. By week 24 it was 17. Following the plan they'd set, his doctors stopped semaglutide there.

Mara: Same dose, same slide, twice. That's what a rechallenge is for.

Eli: So they scored it on the Naranjo scale, a standard checklist for judging whether a drug caused a reaction: the timing, what happened when the drug stopped, what happened when it came back. He scored 7, which counts as probable. Researchers Alanazi and Alanazi call that a disciplined estimate of probability, not a verdict, and say a single report can't establish causation. The short break between courses complicates it too: some drug may have lingered.

Mara: Over a hundred thousand trial patients with no added psychiatric risk, Eli, and one man whose score climbed twice on the same drug.

Appetite for Life

Eli: Two readings sit on those facts, and they come from different people.

Mara: The first belongs to the regulators: the FDA, the European Medicines Agency, Britain's MHRA and Health Canada. In their view, the evidence doesn't establish that these drugs cause psychiatric harm, and mood can shift for other reasons. Rapid weight loss can stir real emotional and biological upheaval.

Eli: And these drugs are built to shrink how much people eat.

Mara: That's its own risk. Strong appetite suppression makes it easy to eat too little without realising, and that deficit can bring fatigue, irritability, poor concentration, less motivation. Nausea and other stomach trouble are common too, and may weigh on mood. A body worn down by its diet, in other words, rather than a drug reaching into the reward circuit.

Eli: Fatigue, less motivation. Much the same words people use for the meh.

Mara: And on average, people seem to do better. Research generally finds improved mood and quality of life on GLP-1s, and a meta-analysis, combining data from multiple studies, of about two thousand people found a small drop in depression scores. Joshua Neal, the same voice on the reward wiring, says the big meta-analysis points to a trend toward improvement in psychological symptoms overall. On anhedonia itself, though, one review calls the human evidence "fragmented." It doesn't establish that these drugs cause it.

Eli: The other reading comes from people including Dina Hirsch and Justin Nepa. Hirsch's point: these drugs dampen the reward people get from food, so they may "inadvertently also dampen other reward-seeking behaviors in other parts of their life."

Mara: Deena Hailoo says that with food's pull gone, some patients ask: now what?

Eli: And Nepa: "The same medication can feel freeing to one person and flattening to another."

Mara: The animal work's blunted reward, put into human words.

Eli: Nepa's summary is careful: "The most honest reading is that anhedonia is biologically plausible and patient-reported, but still under-measured." The FDA's guidance, meanwhile, is to keep taking the medication as prescribed, raise concerns with a health professional, and report any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.

Mara: Under-measured. The trials' blind spot, in a single word.

Eli: So, to the listener's question. Across the big trials, there's no sign these drugs cause psychiatric harm overall, and many people feel better on them. But in some people, quieting the pull of food may reach further, into pleasure and drive themselves. For the man in week six, his doctors judged that reach probable.

Mara: What would sharpen the picture: the first big trials that score pleasure itself. Human studies showing whether the dopamine dampening spills over to every non-food reward, or only some. And regulators taking up emotional flattening as its own question, separate from suicidal thoughts.

Eli: Read into methodological blind spots in randomized anti-obesity trials.

Mara: Follow health with us to see whether clinical trials begin tracking emotional blunting.

Eli: And that's the story. I'm Eli.

Mara: And I'm Mara. Thanks for listening, and until next time.